May 18, 2016
|
Oncobiologics Announces Closing of Initial Public Offering of Units
|
|
May 12, 2016
|
Oncobiologics Announces Pricing of Its Initial Public Offering of Units
|
|
December 14, 2015
|
Oncobiologics Expands Its Board Of Directors With The Appointment Of Three New Independent Members
|
|
October 5, 2015
|
ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial
|
|
September 29, 2015
|
Oncobiologics Secures Financing from Sabby Management, LLC
|
|
September 16, 2015
|
Oncobiologics Appoints Lawrence A. Kenyon as Chief Financial Officer
|
|
July 27, 2015
|
Oncobiologics Secures $31 Million Financing
|
|
July 2, 2015
|
Noted Immunology Expert Joins Oncobiologics as Chief Medical Officer
|
|
May 4, 2015
|
Oncobiologics opens commercial launch manufacturing facility
|
|
April 15, 2015
|
Oncobiologics announces completion of clinical dosing for bevacizumab (Avastin® biosimilar) candidate
|
|